ZYBT revenueFY2025CN¥116.36M
- FY YoY
- -37.6%
ZYBT revenue was CN¥116.36M for fiscal 2025 (ended Dec 31, 2025), down 37.6% from fiscal 2024. It rose in 0 of the last 3 fiscal years.
Zhengye Biotechnology Holding Limited (ZYBT) financials
For fiscal 2025 (ended Dec 31, 2025), Zhengye Biotechnology Holding Limited reported CN¥116.36M of revenue and -CN¥69.78M of net income. Figures are in CNY, the currency of its SEC filings.
- Revenue, FY2025
- CN¥116.36M
- Revenue growth, YoY
- -37.6%
- Net income, FY2025
- -CN¥69.78M
- Net margin
- -60.0%
- Free cash flow, FY2025
- CN¥12.32M
- Cash
- CN¥50.33M
- Total debt
- CN¥9.55M
FY2022FY2025
FY2022FY2025
FY2022FY2025
ZYBT revenue and earnings growth
ZYBT net incomeFY2025-CN¥69.78M
ZYBT net income was -CN¥69.78M for fiscal 2025 (ended Dec 31, 2025), compared with CN¥11.31M in fiscal 2024.
ZYBT EPSFY2024CN¥0.25
- FY YoY
- -63.8%
ZYBT diluted EPS was CN¥0.25 for fiscal 2024 (ended Dec 31, 2024), down 63.8% from fiscal 2023.
ZYBT free cash flowFY2025CN¥12.32M
- FY YoY
- -55.1%
ZYBT free cash flow was CN¥12.32M for fiscal 2025 (ended Dec 31, 2025), down 55.1% from fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | CN¥116.36M | CN¥186.36M | CN¥211.65M | CN¥260.27M |
| Cost of revenue | CN¥92.49M | CN¥95.06M | CN¥94.14M | CN¥112.39M |
| Gross profit | CN¥23.87M | CN¥91.30M | CN¥117.51M | CN¥147.88M |
| Research and development | CN¥18.01M | CN¥12.79M | CN¥11.90M | CN¥13.42M |
| Selling, general and admin | CN¥31.01M | CN¥22.57M | CN¥23.59M | CN¥24.32M |
| Operating income | -CN¥70.51M | CN¥16.44M | CN¥44.99M | CN¥65.83M |
| Interest expense | CN¥3.40M | CN¥4.04M | CN¥4.42M | CN¥2.84M |
| Pre-tax income | -CN¥71.87M | CN¥14.39M | CN¥43.76M | CN¥63.91M |
| Income tax | CN¥11.10M | CN¥924.0K | CN¥6.25M | CN¥8.17M |
| Net income | -CN¥69.78M | CN¥11.31M | CN¥31.46M | CN¥46.73M |
| EPS, basic | - | CN¥0.25 | CN¥0.69 | CN¥1.02 |
| EPS, diluted | - | CN¥0.25 | CN¥0.69 | CN¥1.02 |
| Diluted shares | 47.3M | 45.7M | 45.7M | 45.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | CN¥50.33M | CN¥18.61M | CN¥27.19M | CN¥9.75M |
| Short-term investments | CN¥1.56M | CN¥1.43M | CN¥1.22M | - |
| Receivables | CN¥18.48M | CN¥59.56M | CN¥74.17M | - |
| Inventory | CN¥39.17M | CN¥58.22M | CN¥58.30M | - |
| Current assets | CN¥137.42M | CN¥177.57M | CN¥189.24M | - |
| Total assets | CN¥436.47M | CN¥493.25M | CN¥499.89M | - |
| Current liabilities | CN¥120.48M | CN¥135.91M | CN¥150.23M | - |
| Short-term debt | CN¥700.0K | CN¥7.19M | CN¥79.86M | - |
| Long-term debt | - | CN¥4.80M | CN¥9.99M | - |
| Total debt | CN¥9.55M | CN¥11.99M | CN¥89.85M | - |
| Total liabilities | CN¥129.76M | CN¥140.71M | CN¥160.62M | - |
| Shareholders' equity | CN¥249.85M | CN¥283.96M | CN¥339.27M | CN¥356.87M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | CN¥13.33M | CN¥41.05M | CN¥48.18M | CN¥17.34M |
| Capital expenditures | CN¥1.01M | CN¥13.59M | CN¥7.40M | CN¥27.33M |
| Free cash flow | CN¥12.32M | CN¥27.46M | CN¥40.79M | -CN¥9.99M |
| Investing cash flow | -CN¥12.63M | -CN¥27.66M | -CN¥11.77M | -CN¥27.33M |
| Financing cash flow | CN¥32.31M | -CN¥22.13M | -CN¥18.98M | CN¥13.46M |
| Dividends paid | - | CN¥16.02M | CN¥39.45M | CN¥21.43M |
| Depreciation and amortization | CN¥25.88M | CN¥24.16M | CN¥23.91M | CN¥18.80M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | -37.6% | -12.0% | -18.7% | - |
| Net income growth, YoY | - | -64.0% | -32.7% | - |
| EPS growth, YoY | - | -63.8% | -32.4% | - |
| Gross margin | 20.5% | 49.0% | 55.5% | 56.8% |
| Operating margin | -60.6% | 8.8% | 21.3% | 25.3% |
| Net margin | -60.0% | 6.1% | 14.9% | 18.0% |
| Free cash flow margin | 10.6% | 14.7% | 19.3% | -3.8% |
| Return on equity | -27.9% | 4.0% | 9.3% | 13.1% |
| Return on assets | -16.0% | 2.3% | 6.3% | - |
| Current ratio | 1.14 | 1.31 | 1.26 | - |
| Debt to equity | 0.04 | 0.04 | 0.26 | - |
Source: XBRL data Zhengye Biotechnology Holding Limited files with the SEC, latest filing dated Apr 28, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
ZYBT peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ZYBT | CN¥116.36M | -37.6% | -CN¥69.78M | -60.0% | $73.0M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
ZYBT FAQ
8 questionsWhat is ZYBT revenue?
Zhengye Biotechnology Holding Limited (ZYBT) reported CN¥116.36M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 37.6% from the year before.Is ZYBT profitable?
No. Zhengye Biotechnology Holding Limited reported a net loss of CN¥69.78M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ZYBT have?
Zhengye Biotechnology Holding Limited reported CN¥50.33M in cash and cash equivalents and CN¥9.55M of debt on its most recent balance sheet in SEC filings.How fast is ZYBT revenue growing?
Zhengye Biotechnology Holding Limited's revenue changed -37.6% in fiscal 2025, to CN¥116.36M.What is ZYBT gross margin?
Zhengye Biotechnology Holding Limited's gross profit was CN¥23.87M on CN¥116.36M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 20.5%.What is ZYBT free cash flow?
Zhengye Biotechnology Holding Limited generated CN¥12.32M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of CN¥13.33M less capital expenditures.When did ZYBT last report financial results?
The latest statements here come from Zhengye Biotechnology Holding Limited's 20-F filed on Apr 28, 2026, covering the period ended Dec 31, 2025.Where does this ZYBT financial data come from?
Quantisnow builds these statements from the structured XBRL data Zhengye Biotechnology Holding Limited files with the SEC. It is provided for information only and is not investment advice.